Following the company’s fourth quarter results, National Bank Financial analyst Rupert Merer has downgraded Exro Technologies ...

Following the company’s most recent acquisition, Haywood analyst Neal Gilmer has maintained his “Buy” rating on Organigram.

On March 31, in a research update to clients, Treiber maintained his “Hold” rating and price target of (US) $4.00 on BlackBerry. On April 2, BlackBerry reported its Q4 and fiscal 2024 results. In the ...

HEALWELL AI has made an acquisition that will present the company with immediate upsell opportunities., says Raymond James ...

TD Cowen analyst Vince Valentini says he is feeling more bullish about Quebecor, and has raised his price target on it.

Following the company’s fourth quarter results, Ventum Capital Markets analysts Andrew Semple has maintained his “Buy” rating ...

Delayed financials from WELL Health mean an opportunity for investors, says Ventum Capital Markets analyst Rob Goff.

Ahead of the company’s fourth quarter results, CIBC analyst Todd Coupland has maintained his “Buy” rating and $7.00 price ...

Following the company’s fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has maintained his “Buy” rating on ...

Following the company’s fourth quarter results, ATB Capital analyst Martin Toner has cut his price target on Bitfarms.

Its fourth quarter results are in the books and Ventum Capital Markets analyst Andrew Semple thinks there is still good money ...